IF 4.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Joaquin Bobi, Francisco-Rafael Jimenez-Trinidad, Luis Ortega-Paz, Nuria Cortes-Serra, Iolanda Lazaro, Juan-Jose Rodriguez, Carmen Fernandez-Becerra, Ana García-Álvarez, Manel Sabate, Salvatore Brugaletta, Ana-Paula Dantas
{"title":"Antiangiogenic effect of circulating extracellular vesicles in acute coronary syndrome: Role of miR-199a-3p and miR-125a-5p.","authors":"Joaquin Bobi, Francisco-Rafael Jimenez-Trinidad, Luis Ortega-Paz, Nuria Cortes-Serra, Iolanda Lazaro, Juan-Jose Rodriguez, Carmen Fernandez-Becerra, Ana García-Álvarez, Manel Sabate, Salvatore Brugaletta, Ana-Paula Dantas","doi":"10.1111/eci.70022","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Circulating extracellular vesicles (EVs) have a great impact on human health as biomarkers and messengers in intercellular signalling. We aimed to determine how the miRNA profile of circulating EVs during an acute coronary event interferes with the vasculogenic potential of endothelial cells (EC).</p><p><strong>Approach and results: </strong>EVs were purified from the plasma of patients in the acute phase of non-ST segment elevation myocardial infarction (NSTEMI, n = 33) and from healthy donors (n = 19) used as a control group. Human ECs were treated with EV suspension (5 × 10<sup>7</sup> particles/cm<sup>2</sup>) and tested for their vasculogenic potential and mRNA expression. The EV miRNA profile was determined by miRNA array. EV levels were markedly increased in the plasma of NSTEMI (2.3 × 10<sup>11</sup> ± 1.5 × 10<sup>10</sup> particles/mL) versus control (1.2 × 10<sup>11</sup> ± 1.1 × 10<sup>10</sup> particles/mL; p = .02). Treatment of ECs with control EVs increased migration, tube formation, and shaped more branched vessel-like structures in comparison to Sham-treated ECs. Nevertheless, EVs from NSTEMI lacked their vasculogenic potential. Network analysis of EV miRNA and EC mRNA expression revealed a correlation of increased miR-199a-3p and miR-125a-5p expression with a decrease in components involved in EC sprout and stabilization. Combined therapy with miR-199a-3p and miR-125a-5p decreased EC vasculogenic potential. Moreover, anti-miRNA therapy with a combination of anti-miR-125a-5p and anti-miR-199a-3p restored the vasculogenic potential impaired by NSTEMI EVs.</p><p><strong>Conclusions: </strong>Circulating EVs play an important role in the control of angiogenesis. However, in the acute phase of NSTEMI, intercellular communication via EV is modified and loses its ability to generate new blood vessels. The loss of angiogenic capacity of EVs during NSTEMI may be an important player in the disease progression and outcomes.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70022"},"PeriodicalIF":4.4000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70022","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:循环中的细胞外囊泡(EVs)作为生物标志物和细胞间信号传递的信使,对人体健康有着重大影响。我们的目的是确定在急性冠状动脉事件中,循环EVs的miRNA谱如何干扰内皮细胞(EC)的血管生成潜能:从处于急性期的非ST段抬高型心肌梗死(NSTEMI,n = 33)患者血浆中纯化出EVs,并从作为对照组的健康供体(n = 19)中纯化出EVs。用 EV 悬浮液(5×107 颗粒/平方厘米)处理人类 EC,并检测其血管生成潜能和 mRNA 表达。通过 miRNA 阵列测定了 EV 的 miRNA 图谱。与对照组(1.2 × 1011 ± 1.1 × 1010 颗粒/毫升;p = .02)相比,NSTEMI 患者血浆中的 EV 水平明显升高(2.3 × 1011 ± 1.5 × 1010 颗粒/毫升)。与Sham处理的ECs相比,用对照组EVs处理的ECs增加了迁移和管形成,并形成了更多的分支血管样结构。然而,NSTEMI 的 EVs 缺乏血管生成潜力。对EV miRNA和EC mRNA表达的网络分析显示,miR-199a-3p和miR-125a-5p的表达增加与参与EC萌芽和稳定的成分减少有关。miR-199a-3p和miR-125a-5p的联合疗法降低了EC的血管生成潜能。此外,联合使用抗miR-125a-5p和抗miR-199a-3p的抗miRNA疗法可恢复NSTEMI EVs损害的血管生成潜能:结论:循环EVs在控制血管生成方面发挥着重要作用。然而,在 NSTEMI 急性期,通过 EV 进行的细胞间交流发生了改变,失去了生成新血管的能力。在 NSTEMI 期间,EVs 血管生成能力的丧失可能是影响疾病进展和预后的一个重要因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antiangiogenic effect of circulating extracellular vesicles in acute coronary syndrome: Role of miR-199a-3p and miR-125a-5p.

Objective: Circulating extracellular vesicles (EVs) have a great impact on human health as biomarkers and messengers in intercellular signalling. We aimed to determine how the miRNA profile of circulating EVs during an acute coronary event interferes with the vasculogenic potential of endothelial cells (EC).

Approach and results: EVs were purified from the plasma of patients in the acute phase of non-ST segment elevation myocardial infarction (NSTEMI, n = 33) and from healthy donors (n = 19) used as a control group. Human ECs were treated with EV suspension (5 × 107 particles/cm2) and tested for their vasculogenic potential and mRNA expression. The EV miRNA profile was determined by miRNA array. EV levels were markedly increased in the plasma of NSTEMI (2.3 × 1011 ± 1.5 × 1010 particles/mL) versus control (1.2 × 1011 ± 1.1 × 1010 particles/mL; p = .02). Treatment of ECs with control EVs increased migration, tube formation, and shaped more branched vessel-like structures in comparison to Sham-treated ECs. Nevertheless, EVs from NSTEMI lacked their vasculogenic potential. Network analysis of EV miRNA and EC mRNA expression revealed a correlation of increased miR-199a-3p and miR-125a-5p expression with a decrease in components involved in EC sprout and stabilization. Combined therapy with miR-199a-3p and miR-125a-5p decreased EC vasculogenic potential. Moreover, anti-miRNA therapy with a combination of anti-miR-125a-5p and anti-miR-199a-3p restored the vasculogenic potential impaired by NSTEMI EVs.

Conclusions: Circulating EVs play an important role in the control of angiogenesis. However, in the acute phase of NSTEMI, intercellular communication via EV is modified and loses its ability to generate new blood vessels. The loss of angiogenic capacity of EVs during NSTEMI may be an important player in the disease progression and outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信